The global green ammonia market, valued at USD 2,672 million in 2025, is projected to reach USD 8,002 million in 2026 and USD 55,056 million by 2032, with a 37.91% CAGR during the forecast period 2026 to 2032. In April 2024, ReNew E-Fuels entered into an agreement with JERA to develop a green ammonia production plant in India. In June 2024, Hygenco Green Energies entered into an agreement with Ameropa to boost the former’s green ammonia export, facilitating the worldwide shift towards renew...

The spatial genomics and transcriptomics market, valued at USD 6.5 billion in 2025, is projected to reach USD 7.3 billion in 2026 and USD 20.1 billion by 2035, with a 11.9% CAGR during the forecast period 2026 to 2035. Researchers have focused their efforts from decoding the primary sequence of genes to analyzing the location and interaction of cell types, and biomarkers (primarily, DNA, RNA and proteins), through a process known as spatial phenotyping. These spatial phenotyping platforms can be...

The global 3D cell culture market, valued at USD 2.16 billion in 2025, is projected to reach USD 2.61 billion in 2026 and USD 8.90 billion by 2035, with a 14.6% CAGR during the forecast period 2026 to 2035. Driven by the increasing requirement of animal model alternatives, the 3D cell culture market is anticipated to grow at a higher rate during the forecast period. According to our projection, use of 3d cell culture systems for cancer research is dominating the market and is likely to hold 41%...

The global antiviral drugs market size is estimated to grow from USD 69 billion in 2025 to reach USD 74 billion in 2026 and USD 127 billion by 2035, representing a higher CAGR of 6.1% during the forecast period 2026 to 2035. According to the National Institute for Health’s reports, around 52 million (33%) deaths are caused by infectious diseases annually. COVID-19 is one of the latest examples of an infectious disease that caused 3 million deaths worldwide. Before COVID-19, Human Immunodeficie...

The DNA data storage market size is estimated to be worth USD 34.8 million in 2024 and is expected to reach USD 532 million by 2035 growing at a CAGR of 28% during the forecast period, till 2035. The ongoing technological advancements, rising popularity of social media, use of virtual platforms during the COVID-19 pandemic and digitalization of the various aspects in the modern world have led to the generation of colossal amount of digital data. The reliable and secure storage and accessibility...

The global clinical trial patient recruitment services market, valued at USD 11.8 billion in 2025, is projected to reach USD 12.8 billion in 2026 and USD 26.2 billion by 2035, with a 8.3% CAGR during the forecast period 2026 to 2035. Studies suggest that around 40% of the total investment made for the development of a drug candidate is dedicated to clinical trials. However, around 80% of the clinical trials are delayed due to insufficient patient recruitment. Further, retaining patients is also...

The mitochondrial disease therapies market, valued at USD 518 million in 2025 to reach USD 660 million in 2026 and USD 1,817 million by 2030, with a higher CAGR of 28.8% during the forecast period, 2026 to 2030. Mitochondrial diseases are characterized by chronic, genetic and progressive medical symptoms that arise due to inherited or spontaneous mutations in mitochondrial DNA (a small, circular, double-stranded with ~16,500 base pairs that exists outside of the nucleus). It is worth highlighti...

The global cancer diagnostics market is currently worth around USD 156 billion and is expected to reach USD 319 billion by 2032. It is expected to grow at a CAGR of 9.3% till 2032. According to the American Cancer Society, by 2050, the number of cancer cases will be predicted to increase to 35 million based solely on projected population growth. Further, Studies have indicated that misdiagnosis or late diagnosis can severely impact survival rates, underscoring the critical need for reliable diag...

The global healthcare cold chain logistics market is estimated to grow from USD 197.7 billion in 2024 to reach USD 207.0 billion in 2025 and USD 320.9 billion by 2035, representing a higher CAGR of 4.5% during the forecast period. Given the recent technical breakthroughs and advances, and the steadily rising demand for biopharmaceuticals, the reliance on cold chain is expected to increase substantially, causing logistics service providers to contemplate, devise and implement flexible business st...

The global T-cell therapy market, valued at USD 6.5 billion in 2025, is projected to grow to USD 8.1 billion in 2026 and USD 20.9 billion by 2035, representing a CAGR of 11.2% during the forecast period 2026 to 2035. According to NIH, in 2024, around 2 million people are estimated to be diagnosed with various types of cancer in the U.S. alone. The US FDA approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or r...

Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the women

The NFT in Healthcare market, valued at USD 208 million in 2025, is projected to reach USD 240 million in 2026 and USD 1,117 million by 2035, with a 18.6% CAGR during the forecast period 2026 to 2035. The new research study consists of market trends, porter’s five forces, detailed market analysis, and market sizing and opportunity analysis.

The global site management organization market, valued at USD 12.4 billion in 2025, is projected to reach USD 13.6 billion in 2026 and USD 31.6 billion by 2035, with a 9.8% CAGR during the forecast period 2026 to 2035. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually. Currently, around 250 companies claim to be actively providing SMO services to drug...

The global healthcare simulators market size, valued at USD 3.04 billion in 2024, is projected to reach USD 3.61 billion in 2025 and USD 14.49 billion by 2035, representing a CAGR of 14.9% during the forecast period. It is worth mentioning that the need for healthcare simulators has significantly increased due to the growing medical education systems where practitioners / students can improve their skills using these innovative technologies. Driven by the ongoing demand, several industrial playe...

Currently, more than 40 industrial and non-industrial players are engaged in the development of drugs for polycystic ovary syndrome. Notably, 70% of the industrial players are very large firms. It is worth noting that these industrial players are widely emphasizing symptomatic treatment of polycystic ovary syndrome. However, with widespread demand companies like AstraZeneca are currently evaluating clinical drugs to cure PCOS condition.

The widespread adoption of DNA methylation technologies and broad emphasis on genome research have become crucial growth factors for this industry. It is worth noting that industrial players, such as Pfizer, Roche, QIAGEN are finding key opportunities in this field and focusing on technological innovations to make them more advanced and affordable. For instance, in April 2025, EpiCypher® (a global leader in epigenomic innovation) launched CUTANA® meCUT&RUN and Multiomic CUT&RUN (affordable met...

In Asia-Pacific, the market for non-invasive fat reduction is expected to register a higher CAGR during the forecast period. This lucrative growth is likely to be fueled by the heightened social media influence and adoption of aesthetic procedures for body contouring and fat reduction. Additionally, the companies like AbbVie, and VLCC are expanding their clinical proven technologies such as CoolSculpting Elite and VLCC Lipo-1060 latest laser technology for far reduction, in Asian countries, such...

Majority of the industrial players, such as Abbott Laboratories, B. Braun and Johnson & Johnson are continually accelerating their efforts to develop single use medical kits and other supplies. In order to leverage competitive edge, several industrial players are undertaking strategic initiatives, such as latest product launch, collaborations, and partnerships.For instance, in October 2024, Verathon (subsidiary of Roper Industries) launched first Spectrum QC eco (single-use video laryngoscope) m...

It is important to highlight here that the USFDA has also approved numerous cancer biosimilar products for cancer treatment, such as bevacizumab, rituximab and trastuzumab. Notably, biosimilars of bevacizumab (Avastin®) are presently available with brand name, Alymsys®, Avzivi®, Jobevne™, Mvasi®, Vegzelma® and Zirabev®. The market for oncology biosimilars in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. Notably, the rising prevalence of cancer is expected...

The global veterinary hematology analyzers market is valued at USD 1.03 billion in 2025 and is poised to reach USD 1.74 billion by 2035, expecting to grow at a CAGR of 5.4% during the forecast period. The market is expected to be driven by the rising demand for advanced diagnostics tools, such as veterinary hematology analyzers and handheld analyzers for diagnosing infectious diseases in animals. Driven by the ongoing demand, several market players are expected to strengthen their product portfo...